Zuellig Pharma acquires Hangzhou facility to boost clinical trials
By United One News · AI-generated summary of 2 outlets' reporting
Published · Updated
AI-generated summary of the coverage listed below:
Zuellig Pharma announced the strategic acquisition of a specialized clinical supply facility in Hangzhou, China, to strengthen clinical sourcing capabilities for domestic and international trials on November 4, 2026.
- The newly acquired facility holds a Drug Distribution License to provide local clinical sourcing of comparator and concomitant medications.
- The location features advanced cold-chain capabilities across temperature-controlled capacities ranging from negative twenty to twenty-five degrees Celsius.
- The facility connects to existing regional depots and a global network of over forty-five clinical depots.
- The acquisition aims to streamline billing processes and create value-added tax savings for clinical trial sponsors.
“As clinical trials become increasingly complex, having dependable, integrated infrastructure in the market is essential to support clinical innovation.”
Covered by 2 outlets across the spectrum: 0% left, 100% center, 0% right.
How each side framed it
Indian pharma eyes bigger New Zealand market through FTA─driven regulatory reforms
Timeline
First to report: Pharmabiz (); 2 articles from 2 outlets so far.
Who is covering this story
- Center (2): Pharmabiz, PR Newswire Asia
Sources
- Indian pharma eyes bigger New Zealand market through FTA─driven regulatory reforms — Pharmabiz (center, AI-estimated) ·
- Zuellig Pharma Strengthens Clinical Sourcing Capabilities in China through Strategic Acquisition — PR Newswire Asia (center, AI-estimated) ·